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The human heart has limited regenerative capacity, which makes the reparative response after the cardiac infarction
quite challenging. During the last decade, stem cells have become promising candidates for heart repair, owing to
their potent differentiation capacity and paracrine cytokine secretion. Among the different types of stem cells,
mesenchymal stem cells have high proliferative potential and secrete numerous cytokines, growth factors, and
microRNAs. The paracrine cytokines play important roles in cardiac regeneration, neovascularization, anti-apoptosis,
and anti-remodeling mechanisms, among others. This review summarizes the cytokines secreted by stem cells and
their relative signaling pathways, which represent key mechanisms for heart regeneration and may serve as a
promising future therapeutic strategy for myocardial infarction patients.
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Introduction
Myocardial infarction (MI) causes the loss of cardiac tis-
sue and scar formation, which ultimately lead to heart fail-
ure. According to the World Health Organization, heart
failure initiated by MI and coronary artery disease ac-
counts for 29% of deaths worldwide [1]. However, human
heart tissue does not regenerate spontaneously, thus
“regenerative medicine” represents a promising alternative
treatment for MI [2]. Cardiac tissue regenerative medicine
involves cardiomyocyte regeneration, neovascularization,
and paracrine cytokines, which have anti-inflammatory,
anti-apoptotic, and anti-remodeling effects [3]. During the
last decade, stem cells have become promising candidates
for regenerative medicine not only because of their cap-
acity of differentiation toward cardiomyocyte and vascular
cell lineages but also their capacity for releasing such para-
crine factors and their anti-arrhythmic effects [4,5]. Paracrine
cytokines and chemokines play pivotal roles in stem cell-
related cardiac repair mechanisms.
Although great advances have been made in the identifi-
cation of novel strategies to save the myocardium and im-
prove the mortality of MI patients, further understanding
of the impact of cytokines on myoblast differentiation and* Correspondence: lina82002@126.com
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reproduction in any medium, provided the orthe related signaling pathways may provide unique oppor-
tunities for reducing cardiac impairment.
The current review summarizes the stem cell-related
cytokines and related reparative pathways that represent
potential therapeutic targets for cardiac regeneration
after MI.Cellular sources of cardiac regeneration
Cardiac progenitor cells
Shortly after birth, human cardiomyocytes cease prolifer-
ating and exhibit a very limited regenerative capacity.
However, this concept has been challenged recently.
Bergmann et al. used C14 to carbon date the DNA of div-
iding cardiomyocytes. They demonstrated that the diploid
cardiomyocyte nuclei were younger than the human sub-
jects, providing good evidence for cardiomyocyte division
in adult humans. Mathematical statistics suggested that
approximately 1% of cardiomyocytes were renewed per
year at age 20 years, and 0.4% at age 75 years [6]. Based
on these kinetics, about 45% of cardiomyocytes would be
predicted to be renewed over the normal human lifespan,
whereas 55% would be cells persisting since birth. In the
female heart, myocyte turnover occurs at a rate of 10%,
14%, and 40% per year at 20, 60, and 100 years of age, re-
spectively [7]. After this demonstration of the renewal
capacity in adult heart tissue, the existence of cardiac pro-
genitor cells (CPCs) in postnatal hearts has been reported
by different groups [8]. CPCs have been identified by sur-
face markers such as such as c-KIT, Isl1 cells, or SCA-1his is an Open Access article distributed under the terms of the Creative
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flux fluorescent dye (i.e., side population) [9]. CPCs ex-
pressing the tyrosine kinase receptor c-KIT are the most
extensively investigated subtype [10]. Beltrami et al. has
first identified the c-KIT–positive CSCs in the heart cap-
able of dividing symmetrically and asymmetrically in vitro
and differentiating into myocytes, vascular smooth muscle
cells (SMCs), and endothelial cells (ECs) [11]. Newly dif-
ferentiated cardiomyocytes possess the mechanical and
electric properties of functionally cardiomyocytes, which
improve cardiac function after MI [12]. Some studies indi-
cate that, when transplanted, c-KIT+ cells induce large-
scale regeneration of myocardial infarcts and contribute to
the formation of new myocardium and vessels, whereas
others suggest smaller-scale regeneration [10]. Hatzister-
gos and colleagues demonstrated that MSCs may stimu-
late endogenous CSCs, including c-KIT CSCs and GATA-
4 CSCs, to differentiate into enriched populations of adult
cardioblasts that express Nkx2–5 and troponin I both
in vivo and in vitro [13]. However, clinical applications of
CSCs are limited because of their small number and low
proliferation capacity. Nevertheless, CSCs play a pivotal
role in the maintenance of cardiac homeostasis and repair.
Mesenchymal stem cells
Since the first demonstration that bone marrow-derived
mesenchymal stem cells (MSCs) can generate functional
cardiomyocytes [14], these cells have become a promis-
ing therapeutic candidate for heart disease. In the past
decade, many clinical trials have used MSCs to treat MI
and heart failure. The results have demonstrated clinical
safety and efficacy, but the cardiac function improve-
ments have been limited, ranging from 3% to 15% [15].
Currently, differentiation of MSCs into functional cardi-
omyocytes remains controversial and the rate of myocar-
dial regeneration appears too minor to explain the
significant cardiac function recovery observed after MSC
transplantation following MI. Accumulating evidence
suggests that the MSC cytokine profile exerts beneficial
effects on the prevention of apoptosis and fibrosis as
well as improvement of cardiac function [16-18]. For ex-
ample, Duran et al. recently demonstrated that bone
marrow-derived stem cells improve survival, cardiac
function, and attenuate remodeling through the secre-
tion of pro-angiogenic factors that stimulate endogenous
neovascularization [5].
Induced pluripotent stem cells
Fifteen years ago, Murry et al. first demonstrated that fi-
broblasts could be transdifferentiated into skeletal
muscle in vitro by overexpressing the myogenic tran-
scription factor, MyoD [19]. Subsequently, Yamanaka
and colleagues proved that pluripotent stem cells could
be induced from mouse embryonic or adult fibroblastsby introducing four defined factors, Oct3/4, Sox2, c-Myc,
and Klf4, under embryonic stem cell culture conditions
[20]. While this groundbreaking finding has opened an ex-
citing research area, its clinical applications remain limited
given the transgenic integration and alteration of the en-
dogenous genomic organization. Induced pluripotent stem
cells (iPS) can differentiate into cardiomyocytes via mech-
anisms involving the aforementioned cytokines. The pro-
duction of the iPS by non-viral methods or a combination
of the cytokines may serve as alternatives for iPS cell
therapy.
Under hypoxic conditions, stem cells can release growth
factors and cytokines such as transforming growth factor
(TGF)-β, interleukin (IL)-6, vascular endothelial growth
factor (VEGF), fibroblast growth factor (FGF)-2, hepato-
cyte growth factor (HGF), insulin-like growth factor (IGF),
angiopoietin (Ang)-1, stromal cell-derived factor (SDF)-1,
matrix metalloproteinase (MMP)-9, and tumor necrosis
factor (TNF)-α, among others. These secreted cytokines
exert important anti-apoptosis, anti-inflammatory, and
anti-remodeling effects in a paracrine manner [21].
Cytokines, stem cells, and cardiomyocyte regeneration
Cytokines are small cell-secreted molecules that play
pivotal roles in cell proliferation, differentiation, and
apoptosis [22]. Increasing evidence suggests that stem
cell transplantation may decrease circulating inflamma-
tory cytokines such as TNF-α, IL-6, and IL-1β in re-
sponse to injury. Aggarwal et al. observed that immune
cells co-cultured with MSCs may alter the cytokine se-
cretion profile and finally lead to immunotolerance
in vitro [23]. Among the candidates for positive regula-
tors of cardiomyocyte differentiation, the TGF-β, IL-6,
and chemokine families are the most widely investigated
to date and have been demonstrated to be the key players
in cardiomyocyte regeneration.
TGF-β and cardiomyocyte regeneration
The zebrafish heart shows a remarkable regenerative
capacity compared to the mammalian heart. TGF-β is
expressed during early cardiac development in zebrafish,
which coordinates a wide spectrum of subsequent cellular
steps that are required for efficient cardiac regeneration.
Recently, it was reported that Smad3-dependent TGF-β
signaling orchestrates beneficial effects on cardiomyocyte-
based regeneration to achieve complete heart regeneration
[24]. Downregulation of TGF-β/activin signaling caused a
wide range of cellular phenotypes affecting heart function.
In MI, TGF-β plays a pivotal role in cardiac repair by sup-
pressing inflammation and promoting the myofibroblast
phenotype and extracellular matrix deposition. Myofibro-
blast proliferation results in restoration of cardiac function
after MI. Moreover, TGF-β simultaneously induced myo-
genesis and inhibited adipogenesis in a dose-dependent
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the infarct border zone associated with Smad2, 3, and 4
expression and phosphorylation of Smad1 and 2 [26].
TGF-β1 can induce MSCs to differentiate into either
chondrocytes or SMCs in vitro [27,28]. TGF-β released
from MSCs can promote angiogenesis by stimulating EC
proliferation. However, cell − cell and cell −matrix interac-
tions are necessary for such differentiation to occur, simi-
lar to development of these tissues in vivo [29]. TGF-β1
inhibits adipogenic differentiation of MSCs in monolayer
culture. Recently, Rouhi et al. demonstrated that autolo-
gous serum enhances cardiomyocyte differentiation of rat
bone marrow MSCs cells in the presence of TGF-β1 [30].
Taken together, the TGF-β1 signaling pathway may serve
as a potential therapeutic target for the heart regeneration
process.
IL-6 family of cytokines and cardiomyocyte regeneration
Accumulating data show that the IL-6 family also plays
a key regulatory role in cardiomyocyte regeneration.
The IL-6 family includes leukemia inhibitory factor
(LIF), cardiotrophin-1 (CT-1), IL-6, oncostatin-M, and
neutrotrophin-1/B-cell stimulating factor-3 (NNT-1/BSF-3)
[31,32]. IL-6 has numerous activities. On target cells, IL-6
binds to an 80 kDa IL-6 receptor (IL-6R) associated with a
second protein, gp130, and initiates intracellular signaling
[33]. IL-6 has multiple regulatory functions in the immune
and nervous systems. Furthermore, IL-6 is also involved in
liver regeneration and metabolic homeostasis [34]. Ex-
ogenous recombinant IL-6 influences the proliferation
and differentiation of cultured myoblasts derived from hu-
man or murine muscle via the activation of the STAT3
signaling pathway [35]. Our group recently demonstrated
that IL-6 expression and activation of the STAT3 signaling
pathway in monocytes/macrophages are critical mediators
of macrophage migration and myoblast proliferation dur-
ing muscle regeneration [36].
CT-1 is another member of the IL-6 cytokine family. CT-1
knockdown did not affect infarct size in a murine model,
suggesting that CT-1 does not play an essential role in MI-
related injury. Upregulation of CT-1 in the infarcted myocar-
dium modulates the fibrotic response through the inhibition
of fibroblast proliferation [37]. However, CT-l activates the
Janus kinase/signal transducers and activators of transcrip-
tion (JAK/STAT), mitogen-activated protein (MAP) kinase,
phosphatidylinositol (PI) 3 kinase, and nuclear factor κB
(NF-κB) pathways to exert its hypertrophic and cytoprotec-
tive properties [38].
Chemokines and cardiac regeneration
Chemokines comprise a family of small, highly basic
proteins with strikingly similar tertiary structures [39].
Chemokines are markedly upregulated in healing myo-
cardial infarcts and play important roles in modulatinginfarct angiogenesis and fibrous tissue deposition. In the
CXC chemokine subfamily, the SDF-1α/CXC-chemokine
receptor type 4 (SDF-1α/CXCR4) axis is the best-
understood signaling pathway for cardiogenesis, neovas-
cularization, hematopoiesis, and neuronal development,
as well as endothelial progenitor cell trafficking. SDF-1
is predominantly expressed in the infarct area after MI,
which causes the migration of MSCs into the heart and
may responsible for the improvement of cardiac function
[40]. We previously demonstrated that endothelial nitric
oxide synthase (eNOS) promotes the migration of MSCs
toward the infracted heart through the upregulation of
SDF-1 [41]. However, this SDF-1 − induced MSCs migra-
tion toward the MI area can nearly be abolished by a
PI3K inhibitor and CXCR4 antagonist [40]. Overexpression
of SDF-1 in MSCs promoted angiogenesis and improved
cardiac function in a rat MI model [42].
Cytokines, neovascularisation, and angiogenesis
MI induces inflammation in the infarcted zone and the
accumulation of various factors that promote the angiogen-
esis process. Lai et al. demonstrated that MSC-derived mi-
croparticles increase myocyte viability and reduce adverse
remodeling after myocardial hypoxia-induced injury [43].
These microparticles has been demonstrated to contain cy-
tokines, chemokines, and microRNAs. Neovascularisation
consists of two district processes, vasculogenesis and angio-
genesis. Vasculogenesis is driven by bone marrow-derived
circulating endothelial progenitor cells whereas angio-
genesis is initiated by local ECs proliferating from
existing vasculature. Neovascularisation is stringently
regulated by a variety of cytokines, including the VEGF,
FGF, and Ang families [44]. Here, we summarize the major
cytokines that play pivotal roles in neovascularisation and
angiogenesis.
VEGF
VEGF plays crucial roles in EC proliferation and recruit-
ment, embryonic development, and ischemic tissue dam-
age. VEGF acts through the VEGF receptor (VEGFR) 1 or
VEGFR 2 protein tyrosine kinases. Hypoxia-inducible factor
(HIF)-1 is the key regulator of VEGF expression [45,46].
Five human VEGF isoforms (A, B, C, D, and placental
growth factor [PlGF]) have been produced by differen-
tial splicing of VEGF mRNA. VEFG-A is primarily in-
volved in vascular growth, lymphatic development, and
vascular malformation [47]. Thus VEGF-A has been in-
tensively investigated regarding its role in tumorigenesis
and potential for cancer therapy. While VEGF-C and
VEGF-D regulate the lymphangiogenesis [48]. VEGF ap-
pears to be a critical regulator of EC proliferation [49].
Pretreatment of cardiac scars with gene transfer of VEGF
in addition to the Gata4, Mef2c, and Tbx5 (GMT) en-
hanced the transdifferentiation of rat fibroblasts into
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the transfection cocktail resulted in a 4-fold improvement
in the cardiac ejection fraction [50]. Recently, Ye et al.
demonstrated that VEGF is required for effective cardio-
myocyte differentiation of human iPS [51]. Moreover,
VEGF also mediates the phosphorylation of eNOS, which
is pivotal in the regulation of angioblast and embryonic
EC proliferation [52]. Taken together, VEGF is a key regu-
lator of angiogenesis after cardiac ischemia and warrants
further investigation as a therapeutic target for hypoxia-
induced tissue damage in subsequent clinical trials.
FGF
The FGF protein family exhibits a wide variety of effects.
Among these proteins, acidic FGF (FGF-1) and basic
FGF (FGF-2) are the most critical stimulators of EC prolif-
eration and angiogenesis promotion in cancer and cardiac
hypoxia [53]. FGF is upregulated early after cardiac ische-
mic injury, which suggests that it may be involved in the
regulation of the early inflammatory reaction after MI. Al-
though FGF and VEGF activate different genes and seem
to stimulate different vessel types, these actions are highly
correlated [54]. It has been demonstrated that FGF’s
angiogenic effects are VEGF dependent, while VEGF-
induced tubulogenesis requires FGF signaling [55]. FGF
has been shown to induce neovascularization in a rat
vascular pedicle model [56]. Endothelial progenitor cells
express FGF receptors and it has been demonstrated
that FGF regulates the proliferation and differentiation
of endothelial progenitor cell-like MSCs through the
ERK1/2 signaling pathway [57]. In a murine diabetes
model, the improvement of neovascularization corre-
sponded to the high local expression of FGF and VEGF,
suggesting that these cytokines play key roles in post-
ischemic angiogenesis.
Recently, it was also revealed that MSCs overexpress-
ing granulocyte chemotactic protein (GCP)-2 improved
cardiac function through enhanced angiogenic proper-
ties in a myocardial infarction model [58]. Taken to-
gether, the angiogenic cytokines secreted by MSCs
represent promising therapeutic targets for the treat-
ment of MI patients.
Cytokines and other cardioprotective effects
The cytokines secreted by MSCs also play important
roles in cardiomyocyte apoptosis, cardiac contractility,
cardiac remodeling, and inflammation.
Anti-apoptotic effects
Mirotsou et al. reported that secreted frizzled-related
protein 2 (Sfrp2) promotes myocardial repair by increas-
ing cellular catenin and upregulating expression of anti-
apoptotic genes Birc1b and Bcl2 [59]. Wang et al. have
demonstrated that Hsp20-engineered MSCs are resistantto oxidative stress due to enhanced activation of Akt
and increased secretion of VEGF, FGF-2, and IGF-1 [60].
MSCs pretreated with a combination of growth factors,
including FGF-2, IGF-1, and BMP-2, cause reduced car-
diomyocyte apoptosis under hypoxic conditions and en-
hance the phosphorylation of Akt and cyclic adenosine
monophosphate (cAMP), resulting in better gap junctions
and decreased infarct size [61].
Anti-arrhythmic effects
The anti-arrhythmic potential of MSCs remains contro-
versial. Chang et al. revealed the proarrhythmic potential
of MSC transplantation in an in vitro co-culture system
[62]. Such proarrhythmic effects may be related to the
heterogeneity of MSCs, immaturity of transdifferentiated
MSCs, and contractile dyskinesia between MSCs and in
situ cardiomyocytes. However, Ly et al. contend that
stem cell therapy promotes important anti-arrhythmic
effects if properly applied [63]. Thus, studies regarding
the effects of MSC-related cytokines on arrhythmia need
further assessment. The anti-arrhythmic effects of MSCs
may serve more important clinical applications than
anti-arrhythmic drugs.
Anti-inflammatory effects
After infarct damage, several innate immune pathways
are activated in the infarcted myocardium. Inflammatory
factors such as TGF-β, IL-1β, IL-6, TNF-α, VEGF, and
others are consistently found in the infarct area.
Aggarwal et al. observed that MSC trafficking into the in-
farct area decreases the secretion of TNF-α and interferon-γ,
while increasing IL-4 and IL-10 production [23]. MSC
transplantation also attenuates the activity of NF-κB, in-
hibits the protein production of TNF-α and IL-6, and
increases the expression of IL-10 in infarcted myocar-
dium [64]. MSCs also release heme oxygenase-1 (HO-1)
and eNOS, important anti-oxidative stress factors,
resulting in the protection of cardiomyocytes, improve-
ment of neovascularization, and improvement in cardiac
function during the early stage after MI [65]. The mech-
anisms by which MSCs modulate the immune system
to reduce the inflammatory response warrant further
investigation.
Conclusions
Myocardial regeneration has been intensively studied in
the last decade given the promising results of the stem
cell therapy in MI. Among the mechanisms underlying
the cardioprotective effects of stem cells, the paracrine
cytokines released by stem cells are the most important
factors. This review summarized the major cytokines in-
volved in cardiomyocyte differentiation, angiogenesis,
and neovascularization, as well as anti-apoptotic and
anti-arrhythmic processes. Increased understanding of
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enable the discovery of more beneficial cytokines for
heart regeneration. The full understanding of the related
cytokine signaling pathways and their complex biological
effects will be essential for future clinical applications.
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